Our team has originated or contributed to the discovery and development of a range of drug candidates that moved into clinical development for the following targets: an p53/mdm2 protein-protein interaction inhibitor, dual orexin receptor antagonist (DORAs), a FAS receptor stabilizer, an MTX1 antibody drug conjugate as well as an oral bendamustin anti-cancer drug.
Dr. Lutz Weber, Co-founder, 30 years of biotech leadership experience (Roche, Co-Founder of MorphoChem, NexusPharma, CellProtect, OntoChem, OntoChem IT Solutions, MolGenie). Strong drug discovery related IT and R&D expertise in new drug discovery related technologies, oncology and cardiovascular diseases. Author of >100 scientific publications and >30 patents. https://www.linkedin.com/in/lutzweber
Dr. Wolfgang Richter, Co-founder, has more than 30 years of experience in the biotech industry as a founder and in different key management positions of several life science companies, including Morphochem AG, R&D-Biopharmaceuticals GmbH and TUBE Pharmaceuticals GmbH. His areas of expertise are CMC, preclinical and formulation development, IP management, in- and out-licensing. Dr. Richter is an inventor or co-inventor of many issued patents.
Scientific advisory board
Prof. Dr. Hans-Joachim Böhm, former Head of Chemistry at F. Hoffmann – La Roche AG, Co-Founder and Managing Director of Novomol. Creator of the EDEN platform to discover safe & effective small molecule drug candidates.